Qlife announced on 22 April that a research agreement had been made with Nordsjällands Hospital (NOH), for continued validation of the COVID-19 test.
Qlife speaks at the Healthcare IoT conference on 24 October – managing patient data a vital question for the future!
Every day, the Danish healthcare system produces a large amount of data. In the future, new data sources, such as data from patients, personal health tools and apps, will substantially increase the amount of data even more. In order for a clinic to utilize all this information, it is important that data is presented in a simple and intuitive way and that the data management model is transparent, not least in the context of GDPR. It is about creating experience of collecting and using the new types of data for targeted treatment for the benefit of patients.
Resolution on adoption of accounts and allocation of the company’s result
FINANCIAL SUMMARY FIRST QUARTER 2020
The parties have agreed a testing plan for all players, judges and club staff for Covid-19 in the professional leagues (3F SuperLiga and NordicBet Liga).
Qlife announces that it has entered into a research agreement with Nordsjællands Hospital (NOH), to continue the validation of the Egoo Sars-CoV-2 virus test.
Information regarding the coronavirus
Due to increased requests for information on route to market for Qlife’s COVID-19 test the company is updating the following:
Qlife announces that it has closed a license and supply agreement with Aidian Oy to access and incorporate their patented SIBA® Technology into the Egoo.Health platform.
Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak.